



**May 30, 2026**

To,  
The Manager, Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, C-I Block G, Bandra Kurla Complex, Bandra (East),  
Mumbai-400051, Maharashtra, India

**Scrip Symbol: CURIS ISIN: INE1BZN01016.**

Dear Sir/Mam,

**Sub.: Outcome of Board Meeting held on May 30, 2026:**

**Ref.: Regulation 30 and 33 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015**

We wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 30, 2026 has inter-alia, considered and approved the Audited Standalone Financial Results of the company for the half year and year ended on March 31, 2026.

The aforesaid details will also be hosted on the Company's website viz. <http://curisls.com/>.

The Board meeting commenced at 4.30 P.M. and concluded at 05.30 P.M.

We request you to take the above information on record.

Thanking you,

**FOR CURIS LIFESCIENCES LIMITED**

\_\_\_\_\_  
**DHARMESH DASHARATHBHAI PATEL**  
**MANAGING DIRECTOR**  
**DIN: 07371033**

**Independent Auditor's Report on Audited Standalone Quarterly and Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**TO THE BOARD OF DIRECTORS OF CURIS LIFESCIENCES LIMITED**

**Opinion**

We have audited the accompanying standalone quarterly and annual financial results of **Curis Lifesciences Limited** for the half year and year ended **31<sup>st</sup> March, 2026**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit after tax other financial information for the half year and year ended **31<sup>st</sup> March, 2026**.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting



principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors is also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.




- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For, **B T Vora & Co.**  
Chartered Accountants  
FRN: 123652W



**C. A. SHETH**

Partner

Mem. No.: 180506

**UDIN: 26180506HECKTB7257**

Place: Ahmedabad

Date: 30<sup>th</sup> May, 2026

**CURIS LIFESCIENCES LIMITED**

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

**Statement of Assets and Liabilities**

Rs. In Lakhs

| Particulars                                       | As At 31-03-2026 | As At 31-03-2025 |
|---|------------------|------------------|
|   | Audited          | Audited          |
| <b>EQUITY AND LIABILITIES</b>                     |                  |                  |
| <b>Shareholders' funds</b>                        |                  |                  |
| (a) Share Capital                                 | 808.44           | 593.44           |
| (b) Reserves and Surplus                          | 3927.33          | 1058.32          |
| (c) Money Received against share warrants         | -                | -                |
| <b>Share application money pending allotments</b> | -                | -                |
| <b>Non-Current liabilities</b>                    |                  |                  |
| (a) Long-term Borrowings                          | 557.95           | 749.86           |
| (b) Deferred Tax Liabilities/(Assets) (net)       | 113.34           | 112.10           |
| (c) Long-Term Provisions                          | 4.67             | 6.82             |
| <b>Current liabilities</b>                        |                  |                  |
| (a) Short-term Borrowings                         | 1601.14          | 811.91           |
| (b) Trade Payables                                | 818.06           | 599.98           |
| (c) Other Current Liabilities                     | 75.69            | 118.78           |
| (d) Short-Term Provisions                         | 245.46           | 208.31           |
| <b>Total</b>                                      | <b>8152.07</b>   | <b>4259.52</b>   |
| <b>ASSETS</b>                                     |                  |                  |
| <b>Non-Current Assets</b>                         |                  |                  |
| <b>(a) Property, Plant &amp; Equipments</b>       |                  |                  |
| (i) Tangible Assets                               | 1077.71          | 1099.44          |
| (ii) Capital Work In Progress                     | 132.74           | 1.54             |
| (b) Non-Current Investments                       | 0.50             | 0.50             |
| (c) Other Non Current Assets                      | 27.07            | 22.73            |
| <b>Current Assets</b>                             |                  |                  |
| (a) Inventories                                   | 3410.88          | 1839.97          |
| (b) Trade Receivables                             | 1122.26          | 758.41           |
| (c) Cash and Cash Equivalents                     | 316.51           | 30.36            |
| (d) Short-term Loans and Advances                 | 2064.40          | 506.57           |
| <b>Total</b>                                      | <b>8152.07</b>   | <b>4259.52</b>   |

Date :- 30.05.2026  
Place:- Ahmedabad

For, Curis Lifesciences Limited

**Dharmesh Patel**  
**Managing Director**  
**Din: 07371033**

**CURIS LIFESCIENCES LIMITED**  
(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

Address: PF-23, GIDC Sanand - II, Industrial Estate, Sanand, Ahmedabad, Gujarat, India, 382110

**AUDITED STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE HALF YEAR & YEAR ENDED ON 31st MARCH, 2026**

(Rs. In Lakh except per share data)

| Sr. No.     | Particulars   | For Half Year ended |                |                | Year ended     | Year ended     |
|-------------|---|---------------------|----------------|----------------|----------------|----------------|
|             |   | 31.03.2026          | 30.09.2025     | 31.03.2025     | 31.03.2026     | 31.03.2025     |
|             |   | Audited             | Unaudited      | Audited        | Audited        | Audited        |
| <b>I</b>    | <b>Revenue from Operations</b>  |                     |                |                |                |                |
|             | Net sales or Revenue from Operations  | 3271.99             | 2790.89        | 3436.24        | 6062.88        | 5025.86        |
| II          | Other Income  | 28.03               | 0.12           | 1.11           | 28.15          | 1.23           |
| <b>III</b>  | <b>Total Income (I+II)</b>  | <b>3300.03</b>      | <b>2791.01</b> | <b>3437.34</b> | <b>6091.04</b> | <b>5027.08</b> |
| <b>IV</b>   | <b>Expenses</b>   |                     |                |                |                |                |
| (a)         | Cost of Materials consumed  | 2460.40             | 2061.64        | 2522.93        | 4522.03        | 3376.85        |
| (b)         | Changes in inventories of finished goods, work-in-progress and stock-in-trade   | (476.16)            | (205.90)       | (223.60)       | (682.06)       | (207.22)       |
| (c)         | Purchase of Stock in Trade  | 348.74              | 2.87           | 15.93          | 351.61         | 17.21          |
| (d)         | Employee benefits expenses  | 189.87              | 171.87         | 166.03         | 361.74         | 322.31         |
| (e)         | Finance Costs   | 70.86               | 42.99          | 60.66          | 113.85         | 110.61         |
| (f)         | Depreciation and amortisation expenses  | 35.45               | 34.16          | 33.73          | 69.61          | 67.47          |
| (g)         | Other Expenses  | 234.99              | 161.63         | 261.75         | 396.61         | 442.29         |
|             | <b>Total Expenses (IV)</b>  | <b>2864.15</b>      | <b>2269.25</b> | <b>2837.42</b> | <b>5133.41</b> | <b>4129.52</b> |
| <b>V</b>    | <b>Profit(loss) before exceptional and extraordinary items and tax (III-IV)</b> | <b>435.88</b>       | <b>521.76</b>  | <b>599.92</b>  | <b>957.63</b>  | <b>897.56</b>  |
| VI          | Exceptional items {Prior Year Expenses/(Income)(net)}                           | 1.47                | 0.00           | (3.61)         | 1.47           | (1.24)         |
| <b>VII</b>  | <b>Profit before extraordinary items and tax (V - VI)</b>                       | <b>434.40</b>       | <b>521.76</b>  | <b>603.53</b>  | <b>956.16</b>  | <b>898.80</b>  |
| VIII        | Extraordinary items   | -                   | -              | -              | -              | -              |
| <b>IX</b>   | <b>Profit before tax (VII- VIII)</b>  | <b>434.40</b>       | <b>521.76</b>  | <b>603.53</b>  | <b>956.16</b>  | <b>898.80</b>  |
| <b>X</b>    | <b>Tax Expense</b>  | <b>163.85</b>       | <b>100.67</b>  | <b>203.16</b>  | <b>264.52</b>  | <b>278.16</b>  |
| (a)         | Current tax   | 150.00              | 100.00         | 145.00         | 250.00         | 220.00         |
| (b)         | Current Tax Expense Relating to Prior years                                     | 13.29               | 0.00           | 3.47           | 13.29          | 3.47           |
| (c)         | Deferred Tax (Asset)/Liabilities  | 0.57                | 0.67           | 54.68          | 1.24           | 54.68          |
| <b>XI</b>   | <b>Profit (Loss) for the period (IX-X)</b>                                      | <b>270.55</b>       | <b>421.09</b>  | <b>400.37</b>  | <b>691.63</b>  | <b>620.64</b>  |
| <b>XII</b>  | <b>Paid-up Equity Share Capital (Face Value of Rs. 10 each)</b>                 | <b>808.44</b>       | <b>593.44</b>  | <b>593.44</b>  | <b>808.44</b>  | <b>593.44</b>  |
| <b>XIII</b> | <b>Reserves excluding revaluation reserve</b>                                   |                     |                |                | <b>3927.33</b> | <b>1058.32</b> |
| <b>XIV</b>  | <b>Earning per equity share (for continuing operation)</b>                      |                     |                |                |                |                |
| (a)         | Basic earnings (loss) per share from continuing and discontinued operations     | 4.01                | 7.10           | 7.01           | 10.26          | 10.87          |
| (b)         | Diluted earnings (loss) per share continuing and discontinued operations        | 4.01                | 7.10           | 7.01           | 10.26          | 10.87          |

**Notes on Financial Results:-**

|   |   |
|---|---|
| 1 | The above Standalone financial results of the company, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 30.05.2026. The Statutory Auditors have carried out a Limited Review of the results for the half year & year ended March 31, 2026  |
| 2 | The standalone half yearly financial results include the results for the half year ended 31.03.2026 being the balancing figure between the audited figures in respect of the full year ended 31.03.2026 and unaudited figures of half year ended up to 30.09.2025.  |
| 3 | This statement has been prepared in accordance with the Companies (Accounting Standards) Rules, 2021 (AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable. As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.  |
| 4 | Since the company has only one segment, i.e. Manufacturing of Pharmaceutical Products there is no separate reportable segment as required under AS 17.  |
| 5 | The results for the half year ended on 31st March, 2026 are available on the website of NSE Limited (URL: www.nseindia.com) and also on the company's website (URL: <a href="https://curisls.com/financial-results">https://curisls.com/financial-results</a> ).  |
| 6 | The company has successfully completed its Initial Public Offering (IPO) and the Equity shares are listed on SME Emerge Platform of NSE Limited on 14th November, 2025. The Company made its IPO of 21,50,000 equity shares of face value ₹10/- each at premium of ₹118/- per share, aggregating to ₹ 2752.00 lakhs. The issue is fully and over subscribed and the shares are allotted on 12th November, 2025.   |
| 7 | Earnings per share have been computed in accordance with the Accounting Standard (AS) 20 "Earnings Per Share". The Company issued Fresh IPO of 21,50,000 equity shares on 14-12-2025. Therefore, EPS for March 31, 2026 half year and full year ended is calculated on weighted average method on day basis. The Company issued bonus shares in the ratio of 10 equity shares for every 1 equity share held on 31st December 2024. In accordance with the Standard, the EPS for all periods presented has been adjusted for the issue of bonus shares. The weighted average number of shares for FY 2024-25 includes the effect of fresh issue of 39,494 equity shares on 07.10.2024 (time-weighted and adjusted for the bonus issue). Pursuant to the bonus issue (10:1) made during the FY 2024-25, the EPS for 30th September, 2024 has been restated to ensure comparability. As the Company has no dilutive instruments, basic and diluted EPS are the same. Further, EPS of half year ended of all periods is not annualised. |
| 8 | During last half year ended 31st March, 2026, the company has entered into agreed to make strategic investment in Uninova Lifesciences Private Limited by acquiring 51% of the share capital via share purchase agreement. By this virtue, Uninova Lifesciences Private Limited will become subsidiary of the company upon formalized share agreement. The company has already given 20.655 lacs to promoters for acquisition purpose.  |
| 9 | Previous year's/Period's figures have been re-grouped, re-arranged wherever considered necessary.   |

Date :- 30.05.2026  
Place:- Ahmedabad

For, Curis Lifesciences Limited

**Dharmesh Patel**  
Managing Director  
Din: 07371033

**CURIS LIFESCIENCES LIMITED**  
(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)  
CIN: L24230GJ2016PLC086559

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2026**

(Rs. In Lakhs)

| Particulars  | For the year ended<br>31 March, 2026 |                  | For the year ended<br>31 March, 2025 |                  |
|--|--------------------------------------|------------------|--------------------------------------|------------------|
| <b>A. Cash flow from operating activities</b>                          |                                      |                  |                                      |                  |
| Net Profit / (Loss) before extraordinary items and tax                 |                                      | 956.16           |                                      | 898.80           |
| <b>Adjustments for:</b>  |                                      |                  |                                      |                  |
| Depreciation and amortisation  | 69.61                                |                  | 67.47                                |                  |
| Finance Costs  | 113.85                               |                  | 110.61                               |                  |
| Interest Income on Investment & Advances                               | (23.56)                              |                  | (1.11)                               |                  |
| Dividend Income  | (0.12)                               |                  | (0.12)                               |                  |
| Prior Period Adjustments   | (1.47)                               |                  | (1.24)                               |                  |
| (Profit)/Loss on Sale of Assets  | (0.88)                               |                  | -                                    |                  |
| Foreign Exchange Fluctuation Loss/(Gain)                               | (0.07)                               |                  |                                      |                  |
|  |                                      | <b>157.36</b>    |                                      | <b>175.61</b>    |
| <b>Operating profit / (loss) before working capital changes</b>        |                                      | <b>1113.52</b>   |                                      | <b>1074.41</b>   |
| <b>Changes in working capital:</b>                                     |                                      |                  |                                      |                  |
| <b>Adjustments for (increase) / decrease in operating assets:</b>      |                                      |                  |                                      |                  |
| Inventories  | (1570.90)                            |                  | (943.80)                             |                  |
| Trade Receivables  | (363.85)                             |                  | 245.11                               |                  |
| Short-term loans and advances  | (1557.82)                            |                  | (243.08)                             |                  |
| <b>Sub Total (a)</b>   |                                      | <b>(3492.58)</b> |                                      | <b>(941.77)</b>  |
| <b>Adjustments for increase / (decrease) in operating liabilities:</b> |                                      |                  |                                      |                  |
| Trade payables   | 218.08                               |                  | (147.54)                             |                  |
| Other current liabilities  | (43.09)                              |                  | (13.37)                              |                  |
| Short-term Borrowings  | 789.23                               |                  | (26.91)                              |                  |
| Short Term Provisions  | 0.11                                 |                  | 0.61                                 |                  |
| Long term Provisions   | (2.15)                               |                  | 0.00                                 |                  |
| <b>Sub Total (b)</b>   |                                      | <b>962.18</b>    |                                      | <b>(187.21)</b>  |
| <b>Sub Total (a+b)</b>   |                                      | <b>(2530.40)</b> |                                      | <b>(1128.98)</b> |
|  |                                      | <b>(1416.89)</b> |                                      | <b>(54.57)</b>   |
| <b>Cash flow from extraordinary items</b>                              |                                      |                  |                                      |                  |
| Prior Period Adjustment(Net)   | 1.47                                 |                  | 1.24                                 |                  |
| Income Tax (Paid)/Received (net of refund)                             | (226.18)                             |                  | (149.83)                             |                  |
| <b>Sub- Total</b>  |                                      | <b>(224.71)</b>  |                                      | <b>(148.59)</b>  |
| <b>Net cash flow from / (used in) operating activities (A)</b>         |                                      | <b>(1641.60)</b> |                                      | <b>(203.16)</b>  |

| Particulars   | For the year ended<br>31 March, 2026 |                 | For the year ended<br>31 March, 2025 |               |
|---|--------------------------------------|-----------------|--------------------------------------|---------------|
| <b>B. Cash flow from investing activities</b>                   |                                      |                 |                                      |               |
| Capital expenditure on fixed assets, including capital advances |                                      | (180.19)        |                                      | (9.30)        |
| Interest Income on Investment & Advances                        | 23.56                                |                 | 1.11                                 |               |
| Dividend Income   | 0.12                                 |                 | 0.12                                 |               |
| Proceeds from Sale of assets                                    | 2.00                                 |                 | 0.00                                 |               |
| Proceeds from Non Current Assets                                | (4.34)                               |                 | 5.73                                 |               |
|   |                                      | 21.34           |                                      | 6.96          |
| <b>Net cash flow from / (used in) investing activities (B)</b>  |                                      | <b>(158.86)</b> |                                      | <b>(2.35)</b> |

**CURIS LIFESCIENCES LIMITED**  
(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)  
CIN: L24230GJ2016PLC086559

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2026**

(Rs. In Lakhs)

| Particulars   | For the year ended<br>31 March, 2026 |                | For the year ended<br>31 March, 2025 |               |
|---|--------------------------------------|----------------|--------------------------------------|---------------|
| <b>C. Cash flow from financing activities</b>                     |                                      |                |                                      |               |
| Repayment of Long Term Borrowings                                 | (191.91)                             |                | (120.23)                             |               |
| Issue of Share Capital incl. securities premium (net of expenses) | 2392.37                              |                | 424.96                               |               |
| Interest Paid   | (113.85)                             |                | (110.61)                             |               |
|   |                                      | 2086.61        |                                      | 194.12        |
| <b>Net cash flow from / (used in) financing activities (C)</b>    |                                      | <b>2086.61</b> |                                      | <b>194.12</b> |

|   |  |               |  |                |
|---|--|---------------|--|----------------|
| <b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b> |  | <b>286.16</b> |  | <b>(11.39)</b> |
| Cash and cash equivalents at the beginning of the year                |  | 30.36         |  | 41.75          |
| Effect of exchange differences on restatement of foreign currency     |  |               |  |                |
| Cash and cash equivalents   |  |               |  |                |
| <b>Cash and cash equivalents at the end of the year</b>               |  | <b>316.51</b> |  | <b>30.36</b>   |

|  |  |               |  |              |
|--|--|---------------|--|--------------|
| <b>Reconciliation of Cash and cash equivalents with the Balance Sheet:</b> |  |               |  |              |
| Cash and cash equivalents as per Balance Sheet                             |  | 316.51        |  | 30.36        |
| Less: Bank balances not considered as Cash and cash equivalents            |  |               |  |              |
| <b>Net Cash and cash equivalents</b>                                       |  | <b>316.51</b> |  | <b>30.36</b> |
| Add: Current investments considered as part of Cash and cash equivalents.  |  |               |  |              |
| <b>Cash and cash equivalents at the end of the year</b>                    |  | <b>316.51</b> |  | <b>30.36</b> |

|                                |  |               |  |              |
|--------------------------------|--|---------------|--|--------------|
| <b>Comprises:</b>              |  |               |  |              |
| (a) Cash on hand               |  | 24.75         |  | 28.23        |
| <b>(b) Balances with banks</b> |  |               |  |              |
| (i) In current accounts        |  | 291.77        |  | 2.12         |
| <b>Gross Totals</b>            |  | <b>316.51</b> |  | <b>30.36</b> |

**Notes :**

- 1) The above Cash Flow Statement has been prepared under 'Indirect Method' as set out in the Accounting Standard on 'Cash Flow Statement (AS-3)' issued by Companies (Accounting Standards) Rules, 2006.
- 2) Previous year's figures have been rearranged/regrouped wherever necessary.

Date :- 30.05.2026  
Place:- Ahmedabad

For, Curis Lifesciences Limited

Dharmesh Patel  
Managing Director  
Din: 07371033